BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27244682)

  • 1. BRCA1 and BRCA2 Testing Among Young Breast Cancer Survivors.
    Kehl KL; Giordano SH
    JAMA Oncol; 2016 May; 2(5):688-9. PubMed ID: 27244682
    [No Abstract]   [Full Text] [Related]  

  • 2. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes.
    Nomizu T; Matsuzaki M; Katagata N; Kobayashi Y; Sakuma T; Monma T; Saito M; Watanabe F; Midorikawa S; Yamaguchi Y
    Breast Cancer; 2015 Sep; 22(5):557-61. PubMed ID: 23242612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2.
    Kaldate R; Huston A; McCoy H; Cardeiro D; Noyes K
    Breast J; 2014; 20(3):325-6. PubMed ID: 24708220
    [No Abstract]   [Full Text] [Related]  

  • 5. Germline
    Wiggins J; McLoughlin A; George A; Ring A; Kemp Z
    J Med Genet; 2020 Aug; 57(8):528-530. PubMed ID: 31511339
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
    J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution.
    Mislowsky A; Domchek S; Stroede C; Bergey MR; Sonnad SS; Wu L; Tchou J
    Ann Surg Oncol; 2011 Mar; 18(3):745-51. PubMed ID: 20972632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
    Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
    J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Reach of Genetic Cancer Risk Assessment as a Tool for Precision Management of Hereditary Breast Cancer.
    Blazer KR; Slavin T; Weitzel JN
    JAMA Oncol; 2016 Jun; 2(6):723-4. PubMed ID: 26869327
    [No Abstract]   [Full Text] [Related]  

  • 12. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
    Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation.
    Senst N; Llacuachaqui M; Lubinski J; Lynch H; Armel S; Neuhausen S; Ghadirian P; Sun P; Narod SA;
    Clin Genet; 2013 Jul; 84(1):43-6. PubMed ID: 23066998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Armstrong K; Weber BL
    Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
    [No Abstract]   [Full Text] [Related]  

  • 16. Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.
    Hadar T; Mor P; Amit G; Lieberman S; Gekhtman D; Rabinovitch R; Levy-Lahad E
    JAMA Oncol; 2020 Sep; 6(9):1460-1463. PubMed ID: 32644100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1-BRCA2 mutation analysis results in 910 individuals: Mutation distribution and 8 novel mutations.
    Solmaz AE; Onay H; Yeniay L; Gökmen E; Özdemir N; Alanyalı S; Oktay A; Özsaran Z; Kapkaç M; Özkınay F
    Cancer Genet; 2020 Feb; 241():20-24. PubMed ID: 31954625
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic testing for BRCA1 and BRCA2 in the Province of Ontario.
    Finch A; Wang M; Fine A; Atri L; Khalouei S; Pupavac M; Rosen B; Eisen A; Elser C; Charames G; Metcalfe K; Chang MC; Narod SA; Lerner-Ellis J
    Clin Genet; 2016 Mar; 89(3):304-11. PubMed ID: 26219728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
    Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
    Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.